Navigation Links
Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
Date:3/4/2009

CALGARY, March 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY) ("Oncolytics" or the "Company") today reported its financial results for the year ended December 31, 2008.

"In 2008, we selected our first pivotal program for REOLYSIN(R)," said Dr. Brad Thompson, President and CEO of Oncolytics. "The selection of head and neck cancers was supported by interim results reported in our US and UK clinical studies, and the successful development of a manufacturing process capable of supplying REOLYSIN for large clinical studies."

    Selected Highlights:

    Clinical Trial Results
    ----------------------

    -   Announced positive interim results from our Phase I/II UK combination
        REOLYSIN and carboplatin/paclitaxel trial. Of 14 patients evaluable
        for response, four had partial responses and five patients had stable
        disease. Of note, all partial responses and 4/5 stable diseases were
        in head and neck disease;

    -   Announced positive interim results from our UK combination REOLYSIN
        and docetaxel trial. Of the 11 patients evaluable for response, five
        had partial or minor responses, and six patients had stable disease;
        and

    -   Exceeded the primary statistical endpoint in our US multicentre,
        Phase 2 clinical trial to evaluate the intravenous administration of
        REOLYSIN in patients with various sarcomas that had metastasized to
        the lung. We reported that of 33 patients evaluable for response,
        five had stable disease for more than six months, and an additional
        10 patients had stable disease ranging from 3-6 cycles
        (cycle = 28 days).

    Clinical Trial Progress
    -----------------------

    -   Selection of first pivotal program using REOLYSIN in combination with
        paclitaxe
'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 Pacific Northwest ... Summary Global Markets Direct,s, ,Pacific Northwest ... provides an overview of the Pacific Northwest Biotechnology, ... report provides comprehensive information on the current therapeutic ... with comparative analysis at various stages, therapeutics assessment ...
(Date:9/30/2014)... 2014 Shimadzu Scientific Instruments has ... and highly precise tool for measuring displacement in ... With 1000-mm maximum movement distance, the DSES-1000 can ... gauge length of 10 mm. In addition, it ... 50-mm stroke and within +/- 100 µm below ...
(Date:9/30/2014)... the last decade, the laboratory filtration market is experiencing ... acceptance of new filtration technologies in end users market. ... catalyzing the growth of laboratory filtration market. , The ... a strong CAGR during the forecast period of 2014-2019 ... 2019. The market is mainly driven by the increasing ...
(Date:9/30/2014)... California (PRWEB) September 30, 2014 ... the level of each type of cholesterol carrier or ... the presence of excessive cholesterol levels in the body, ... precursor condition to heart attack and other cardiovascular disorders. ... worldwide, therefore testing for cholesterol levels on a regular ...
Breaking Biology Technology:Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4
... Oct. 19, 2011 Physicians and scientists from ... released the results of their groundbreaking research study ... Embryonic Reproductive Potential While Blastocyst Biopsy Does Not: ... Non-Biopsied Sibling Embryos.   The study, led by ...
... Oct. 19, 2011 Intellect Neurosciences, Inc. (OTCPK: ILNS) announces ... presenting at the 10TH Annual BIO Investor Forum.  Hosted by ... Forum features leading private and emerging public companies. The meeting ... San Francisco, Calif. Dr. Chain will be presenting on October ...
... JOSE, Calif., Oct. 19, 2011 Process automation specialist ... US company that develops, produces and distributes sensors, hardware ... intends to strengthen its position in the area of ... increasingly important role in the future, not only in ...
Cached Biology Technology:Revolutionary IVF Study May Change the Way Embryos are Biopsied for Genetic Disease 2Revolutionary IVF Study May Change the Way Embryos are Biopsied for Genetic Disease 3Intellect Neurosciences, Inc. to Present at 10TH Annual BIO Investor Forum 2Intellect Neurosciences, Inc. to Present at 10TH Annual BIO Investor Forum 3Endress+Hauser and Finesse Solutions Form Strategic Partnership - Swiss Process Automation Provider Invests in US Biotech Company 2Endress+Hauser and Finesse Solutions Form Strategic Partnership - Swiss Process Automation Provider Invests in US Biotech Company 3
(Date:9/30/2014)... engineers, led by Clemson University associate professor Brian ... from the U.S. Department of Energy,s Experimental Program ... positive impact on South Carolina in the advancement ... , "Understanding the scientific and engineering needs for ... nuclear technologies is imperative if South Carolina is ...
(Date:9/30/2014)... of Medicine reports positive results of a phase ... subset of lung cancer marked by rearrangement of the ... with advanced non-small cell lung cancer testing positive for ... with 3 complete responses and 33 partial responses. Median ... disease to resume its growth after being slowed by ...
(Date:9/30/2014)... German . ... foods in the world. Because they grow underground, people use ... smell of truffles is not only of interest to gourmets. ... of the Goethe University Frankfurt have discovered that the smell ... are trapped inside truffle fruiting bodies. , White truffles from ...
Breaking Biology News(10 mins):Researchers get $5.25 million to advance nuclear technologies in South Carolina 2NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2On the trail of the truffle flavor 2
... vessel Polarstern has returned today to Bremerhaven from the ... vessel ever both the Northeast and the Northwest Passages ... of the research vessel,s 23rd Arctic expedition, operated by ... its journey on August 12th in Reykjavik and ended ...
... LEDs may help reduce skin ... in Germany are describing a potential alternative to Botox ... scheduled for the November 5 issue of ACS, ... that high intensity visible light from light emitting diodes ...
... microstructure, and prepare to be surprised. Known for its ... "It is intrinsic to the material," says Carolyn ... WisconsinMilwaukee (UWM). "A pit can begin to develop from ... The pitting is cause for concern for industry because ...
Cached Biology News:Research around the North Pole 2Research around the North Pole 3American Chemical Society Weekly PressPac Oct. 15, 2008 2American Chemical Society Weekly PressPac Oct. 15, 2008 3American Chemical Society Weekly PressPac Oct. 15, 2008 4American Chemical Society Weekly PressPac Oct. 15, 2008 5American Chemical Society Weekly PressPac Oct. 15, 2008 6American Chemical Society Weekly PressPac Oct. 15, 2008 7American Chemical Society Weekly PressPac Oct. 15, 2008 8Nanoscale coating protect products -- and the economy 2Nanoscale coating protect products -- and the economy 3Nanoscale coating protect products -- and the economy 4
Mouse monoclonal [6G11] to Cytohesin 1 + 2 ( Abpromise for all tested applications)....
HNF-1 Purified Anti-Mouse, Anti-Rat, Anti-Rabbit, Anti-Human clone 2, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Recombinant Porcine IL-1 alpha/IL-1F1, CF...
... siRNA Custom Synthesis Service provides ... RNA to knockdown any gene. ... RNA base pairs with terminal ... or other lengths of your ...
Biology Products: